News
2d
Investor's Business Daily on MSNWhy Vertex Pharma Is Feeling The Pain Despite A Second-Quarter BeatVertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...
Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...
2d
GlobalData on MSNVertex’s Journavx successor culled after falling short in Phase II trialTopline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...
The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...
3don MSN
Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multiple new product launches," noting $2.96 billion in ...
The outcome of the study was just one setback reported by Vertex as it updated investors on its second-quarter results, ...
Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results